Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
06 janv. 2020 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results
13 nov. 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock
25 oct. 2019 16h30 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
23 oct. 2019 09h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
22 oct. 2019 16h01 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome
02 oct. 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome
24 sept. 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
19 sept. 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results
07 août 2019 16h05 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome
25 juil. 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for...